Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Morepen Lab jumps after subsidiary inks JV with UAE firm     Back
(09 Sep 2025)
The proposed joint venture company, to be incorporated in India, will focus on manufacturing, trading and selling medical devices. Both partners will contribute equally in the share capital of the new entity, with Morepen Laboratories holding an indirect 30% stake through its subsidiary.

The company clarified that the joint venture will be treated as a related party but its promoters have no direct interest apart from their shareholding in Morepen Medipath.

Morepen Laboratories is a vertically integrated pharmaceutical and healthcare company delivering APIs, branded generics, medical devices, and consumer wellness products worldwide.

On a consolidated basis, net profit of Morepen Laboratories declined 70.28% to Rs 10.75 crore while net sales declined 6.59% to Rs 425.24 crore in Q1 June 2025 over Q1 June 2024.

Top